Pembrolizumab-CRT: The New Standard of Care in Locally Advanced Cervical Cancer?

MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...

Market Touch Signal is a free discovery window from Oy Market Touch Ltd. Practical intelligence, clear communication and useful digital ventures: https://market-touch.org/
Get In Touch

Market Touch Signal · Finland · international digital desk

+358 400 512311

info@market-touch.org

Follow Us
Flickr Photos
© 2026 Oy Market Touch Ltd. · Market Touch Signal